Synthesis, in vitro evaluation of cytotoxicity and radiosensitizer activity of novel 2-(2, 4-dinitrobenzylidene) cyclohexanone derivatives against the radioresistant HT29 cell line under aerobic condition

Document Type: Original Article

Authors

1 Medicinal Chemistry Department, School of Pharmacy Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Medical Physics Department, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Introduction: Bifunctional radiosensitizer agents in which nitroaromatic moieties are attached through a linker to antineoplastic moieties have demonstrated higher cytotoxicity and radiosensitizer effects than the corresponding counterparts. This study was conducted to investigate the cytotoxicity and radiosensitizer activities of 2, 4-dinitrobenzene as a radiosensitizer moiety which connected to α, β unsaturated aryl ketones against the radioresistant human HT29 colon cancer cells.
Methods: A series of bifunctional radiosensitizer derivatives that are composed of electron-affinic 2, 4-dinitrophenyl moiety and thiol reactive unsaturated conjugated ketones were prepared. The designed compounds were synthesized by the reaction of the corresponding 2, 4-dinitrobenzaldehyde, cyclohexanone and different aryl aldehydes. The cytotoxicity and radiosensitizer activity of the tested compounds were examined against HT29 colon cancer cells under aerobic condition. The IC50 value of the tested compounds and percent of survival cells were analyzed by the MTT assay. The clonogenic assay was used to assess the cell viability following treatment with the tested compounds with or without the combination of radiation.
Results:This approach demonstrated that the tested compounds at the concentrations utilized have little or no cytotoxicity towards the radioresistant HT29 cell line but have great cytotoxicity and radiosensitizer activity when combined with irradiation.
Conclusion: The novel bifunctional unsaturated conjugated aryl ketones which are thiol alkylators found to exhibit radiosensitivity activity. Consequently, these new developed compounds should be evaluated further to assess their potential efficacy with radiotherapy to combat malignancies in a pre-clinical animal model.

Keywords

Main Subjects


  1. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand? Radiother Oncol. 1997 Apr;43(1):1-21.
  2. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.  Mol Med Today. 2000 Apr;6(4):157-62. Review.
  3. Papadopoulou MV, Bloomer WD. Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs. Drugs Future 2004, 29(8): 807-819.
  4. Isa N. Evidence based radiation oncology with existing technology. Rep Pract Oncol Radiother. 2013 Oct 14;19(4):259-66.
  5. Han EY, Paudel N, Sung J, Yoon M, Chung WK, Kim DW.  Estimation of the risk of secondary malignancy arising from whole-breast irradiation: comparison of five radiotherapy modalities, including TomoHDA. Oncotarget. 2016 Apr 19;7(16):22960-9.
  6. Zabihzadeh M, Birgani MJ, Hoseini-Ghahfarokhi M, Arvandi S, Hoseini SM, Fadaei M. Dosimetric characteristics of 6 MV modified beams by physical wedges of a siemens linear accelerator. Asian Pac J Cancer Prev. 2016;17(4):1685-9.
  7. Sehgal RK, Webb MW, Agrawal KC. Potential radiosensitizing agents. 2. synthesis and biological activity of derivatives of dinitroimidazole with oxiranes. J Med Chem. 1981 May;24(5):601-4.
  8. El-Said MS, El-Gazzar MG, Al-Dosari MS, Ghorab MM. Synthesis, anticancer activity and radiosensitizing evaluation of some new 2-pyridone derivatives. Arzneimittelforschung. 2012 Mar;62(3):149-56.
  9. Ghorab MM, Ragab FA, Heiba HI, El-Gazzar MG, Zahran SS. Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives.  Eur J Med Chem. 2015 Mar 6;92:682-92.
  10. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides.  J Natl Cancer Inst. 1996 Sep 4;88(17):1193-203.
  11. Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, Bauer M, Strauss A, Jonat W, Maass N, Mundhenke C. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer. 2010 Aug 9;10:412.
  12. Palacios DA, Miyake M, Rosser CJ. Radiosensitization in prostate cancer: mechanisms and targets. BMC Urol. 2013 Jan 26;13:4.
  13. Thomas CD, Chavaudra N, Martin L, Guichard M. Correlation between radiosensitivity, percentage hypoxic cells and pO2 measurements in one rodent and two human tumor xenografts. Radiat Res. 1994 Jul;139(1):1-8.
  14. Adams GE, Cooke MS. Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol Relat Stud Phys Chem Med. 1969 Jul;15(5):457-71.
  15. Lee HH, Palmer BD, Wilson WR, Denny WA. Synthesis and hypoxia cytotoxicity of a 2-nitroimidazole mustard. Bioorg Med Chem Lett. 1998 Jul 7;8(13):1741-4.
  16. Ahmed I, Jenkins TC, Walling JM, Stratford IJ, Sheldon PW, Adams GE, Fielden EM. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1079-81.
  17. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 9- [3-(2- Nitro-1- imidazolyl) propylamino]-cyclopenteno[b] quinoline hydrochloride (NLCPQ-1). a novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res. 1996;8(10-11):425-34.
  18. Khalaj A, Doroudi A, Ostad SN, Khoshayand MR, Babai MR, Adibpour N.  Synthesis aerobic cytotoxicity and radiosensitizing activity of novel 2, 4-dinitrophenylamine tethered 5-fluorouracil and hydroxyurea. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6034-8.  
  19. Adbi K, Khalaj A, Ostad SN, Khoshayand MR. Cytotoxicity and radiosensitizing activity of synthesized dinitrophenyl derivatives of 5-fluorouracil. Daru. 2012;20(1):3.
  20. Das U, Doroudi A, Das S, Bandy B, Balzarini J, De Clercq E, Dimmock JR.  E, E-2-Benzylidene-6-(nitrobenzylidene) cyclohexanone: synthesis, cytotoxicity and an examination of some of their electronic, steric and hydrophobic properties. Bioorg Med Chem. 2008 Jun 1;16(11):6261-8.
  21. Das U, Doroudi A, Gul HI, Pati HN, Kawase M, Sakagami H, Chu Q, Stables JP, Dimmock JR. Cytotoxic 2-benzylidene-6-(nitrobenylidene) cyclohexanones which display substantially greater toxicity for neoplasms than non-malignant cells. Bioorg Med Chem. 2010 Mar 15;18(6):2219-2224.
  22. Lambin P, Malaise EP, Joiner MC. Might intrinsic radioresistance of human tumour cells be induced by radiation? Int J Radiat Biol. 1996 Mar;69(3):279-90.
  23. Abdi K, Khalaj A, Ostad SN, Lamei   N, Khoshayand MR. Synthesis, in vitro aerobic and hypoxic cytotoxicity and radiosensitizing activity of novel metronidazole tethered 5-fluorouracil. Daru. 2013 Dec 20;21(1):76.
  24. Doroudi, A, Erfani M, Mousavinia SM. The radiosensitivity effect of hydroxyurea on HT29 cell line. IOSR J Pharm 2015;5(4):40-43.
  25. Dimmock JR, Sidhu KK, Chen M, Li J, Quail JW, Allen TM, Kao GY. Synthesis and cytotoxic evaluation of some cyclic arylidene ketones and related oximes, oxime esters, and analogs. J Pharm Sci. 1994 Jun;83(6):852-8.
  26. Quail JW, Doroudi A, Pati HN, Das U, Dimmock JR.   (E, E)-2-(4-fluorophenylmethylene)-6-(4-nitrophenylmethylene) cyclohexanone.  Acta Cryst. 2005;E61(6):1774-76.
  27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55-63.
  28. Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury Cancer Lett. 2012;327(1-2):48-60.
  29. Pollom EL, Deng L, Pai RK, Brown JM, Giaccia A, Loo BW, Shultz DB, Le QT, Koong AC, Chang DT. Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):568-76.
  30. Erfani M, Doroudi A, Dinari MA, Shirmardi SP. Preparation of a rhenium-188 labeled bisphosphonate for bone pain palliation therapy. J Radioanal Nucl Chem. 2015;303(3):2027-32.
  31. Erfani, M, Rahmani N, Doroudi A, Shafiei M. Preparation and evaluation of rhenium-188-pamidronate as a palliative treatment in bone metastasis.  Nucl Med Biol 2017;49:1-7.
  32. Kurutas EB. The importance of antioxidant which play the role in cellular response against oxidative/nitrosative stress: current state. Nutr J. 2016 Jul 25;15(1):71.
  33. Lu JM, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med. 2010 Apr;14(4):840-60.
  34. Esterbauer H, Zollner H, Scholz N. Reaction of glutathione with conjugated carbonyls. Z Naturforsch C. 1975 Jul-Aug;30(4):466-73.
  35. Monks TJ, Lau SS. Reactive intermediates and their toxicological significance. Toxicology. 1988 Nov 14;52(1-2):1-53.
  36. Mutus B, Wagner JD, Talpas CJ, Dimmock JR, Philips OA, Reid RS. 1-p-chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiols but reversibly with small molecular weight thiols. Anal Biochem. 1989 Mar;177(2):237-43.
  37. Dimmock JR, Kandepu NM, Nazarali AJ, Motaganahalli NL, Kowalchuk TP, Pugazhenthi U, Prisciak JS, Quail JW, Allen TM, LeClerc R, Santos CL, De Clercq E, Balzarini J. Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds. J Med Chem. 2000 Oct 19;43(21):3933-40.
  38. Karki SS, Das U, Imamura N, Sakagami H, Iwamoto S, Kawase M, Balzarini E, De Clercq E, Dimmock SG, Dimmock JR. 3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: a novel class of potent tumor-selective cytotoxins. J Med Chem. 2016 Jan 28;59(2):763-9.
  39. Santiago-Vasquez Y, Das U, Varela-Ramirez A, Baca ST, Ayala-Marin Y, Lema C, Das S, Baryyan A, Dimmock JR, Aguilera RJ. Tumor-selective cytotoxicity of a novel pentadiene analogue on human leukemia/lymphoma cells.  Clin Cancer Drugs. 2016;3(2):138-146.